Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Multiple Myeloma Side Effect- Resolve Blood Clots (VTE)
“VTE (blood clots) is common in patients with multiple myeloma receiving IMiDs, and can cause disability, delay or complicate chemotherapy, and—in rare cases—be fatal.”
Blood clots can be a multiple myeloma side effect of chemo. In 2/94 I was diagnosed with an incurable blood cancer called multiple myeloma (MM). Three years of aggressive therapies. More toxicity than you can imagine. In and out of remission until finally, “there is nothing more that we can do for you…”
From my diagnosis of multiple myeloma in ’94 through those fateful words in ’97, I thought my health was only about my cancer. The fact is that most cancer survivors don’t die from cancer. Cancer survivors die from the problems caused by the cancer itself. Or we die from problems caused by chemotherapy and radiation. A blood clot can be caused by either the multiple myeloma (symptom) or by chemotherapy (MM side effect).
Venous Thromboembolism (VTE) and Deep Vein Thrombosis (DVT) are good examples.
I am a long-term MM survivor and MM Coach. Learn about those conventional (FDA approved) and non-conventional therapies that can help you manage your MM and minimize collateral damage such as blood clots.
In April of 1995, shortly after I began chemotherapy (induction therapy), I developed a blood clot in my thigh. I developed another blood clot (in the other leg) about two years later.
I live an anti-MM, anti-blood clot lifestyle through nutrition, supplementation, bone health, and mind-body therapies. Everything I do is supported by research.
When I met with my doctor about my blood clot back in ’98, he told me that the standard-of-care for a blood clot was to take a blood thinner called warfarin/coumadin. He said I would have to take warfarin/coumadin for the rest of my life. I went to my PC, searched coumadin, learned of the serious long-term side effects of this drug. I chose not to take this warfarin.
After some research I decided that I could manage my blood clot without the possibility of the side effects from long-term warfarin/coumadin use. I began supplementing with Omega-3 Fatty Acids
My clots slowly shrank and disappeared over the next few years.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
Do you have a DVT or a VTE? Scroll down the page, post a question or comment and I will reply to you ASAP.
Thank you,
David Emerson
- MM Survivor,
- MM Cancer Coach,
- Director PeopleBeatingCancer
Recommended Reading:
- Green Tea, Curcumin as Integrative, Synergistic Cancer Therapy
- Understanding Blood Clots/VTE and Multiple Myeloma
- Deep Vein Thrombosis, Venous Thromboembolism aka Blood Clot in cancer patients and survivors
Venous Thromboembolism (VTE)
“The precise number of people affected by VTE is unknown, but estimates range from 300,000 to 900,000 annually in the United States. Almost half of all VTEs occur either during or soon after discharge from a hospital stay or surgery. An estimated 60,000-100,000 Americans die of VTE each year.”
“Cancer-associated thrombosis accounts for almost one-fifth of all cases of venous thromboembolism (VTE) and is a leading cause of death, morbidity, delays in care, and increased costs.”
Hyperviscosity syndrome
“Hyperviscosity syndrome (HVS) is a combination of clinical signs and symptoms related to increased blood viscosity. It can result from abnormal plasma components such as paraproteins (seen in Waldenstrom’s macroglobulinemia [WM] and multiple myeloma [MM]) or immune complexes (systemic lupus erythematosis). HVS can also be secondary to increased cellular components due to leukemia or myeloproliferative disorders.
Clinical features
The classic triad of symptoms includes
- neurologic abnormalities (headache, syncope, seizure, vertigo, hearing loss, stupor, stroke)
- vision changes and
- mucocal bleeding.
New Tool to Predict And Prevent Blood Clots in Multiple Myeloma Patients
“Venous blood clots (known as VTE: venous thromboembolism) are associated with immunomodulatory drug treatment (IMiD) combined with moderate-high steroid dosage.
“VTE is common in patients with multiple myeloma receiving IMiDs, and can cause disability, delay or complicate chemotherapy, and—in rare cases—be fatal.” –Dr. Ang Li, University of Washington
The study’s senior author Kristen M. Sanfilippo, MD, MPHS was “surprised [to find] that prophylactic anticoagulation, in any form, is under-utilized despite of its inclusion in the NCCN Guidelines for Cancer-Associated VTE for more than 10 years now…”
Serious risks from common IV devices mean doctors should choose carefully, experts say
“PICC risks under-recognized-The name PICC stands for peripherally inserted central catheter. The IV device in the arm is a thin tube that is threaded through veins and ends near the heart. It can deliver chemotherapy, antibiotics or even liquid nutrition into the bloodstream, and makes it easy to take blood samples…”
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
“Purpose To provide current recommendations about the prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer…
Recommendations Most hospitalized patients with active cancer require thromboprophylaxis throughout hospitalization. Routine thromboprophylaxis is not recommended for patients with cancer in the outpatient setting. It may be considered for selected high-risk patients. Patients with multiple myeloma receiving antiangiogenesis agents with chemotherapy and/or dexamethasone should receive prophylaxis with either low–molecular weight heparin (LMWH) or low-dose aspirin”
